Should I buy or sell Alaunos Therapeutics stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alaunos Therapeutics in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" TCRT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TCRT, but not buy additional shares or sell existing shares. View TCRT analyst ratings or view top-rated stocks .

What is Alaunos Therapeutics' stock price target for 2024?

3 brokerages have issued 1 year price targets for Alaunos Therapeutics' shares. Their TCRT share price targets range from $45.00 to $45.00. On average, they predict the company's stock price to reach $45.00 in the next twelve months. This suggests a possible upside of 2,012.7% from the stock's current price. View analysts price targets for TCRT or view top-rated stocks among Wall Street analysts .

How have TCRT shares performed in 2024?

Alaunos Therapeutics' stock was trading at $1.0605 at the beginning of 2024. Since then, TCRT stock has increased by 100.8% and is now trading at $2.13. View the best growth stocks for 2024 here .

When is Alaunos Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 5th 2024. View our TCRT earnings forecast .

How were Alaunos Therapeutics' earnings last quarter?

Alaunos Therapeutics, Inc. (NASDAQ:TCRT) posted its quarterly earnings data on Tuesday, November, 14th. The company reported ($0.60) earnings per share for the quarter, missing analysts' consensus estimates of ($0.45) by $0.15.

When did Alaunos Therapeutics' stock split?

Shares of Alaunos Therapeutics reverse split on Thursday, February 1st 2024. The 1-15 reverse split was announced on Thursday, February 1st 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, February 1st 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Who are Alaunos Therapeutics' major shareholders?

Alaunos Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Commerce Bank (2.72%), Magnolia Capital Advisors LLC (0.17%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Kevin S Sr Boyle and Robert W Postma. View institutional ownership trends .

How do I buy shares of Alaunos Therapeutics?

Shares of TCRT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Positive News SentimentPositive News

NASDAQ:TCRT

Alaunos Therapeutics (TCRT) Stock Price, News & Analysis

$2.13

-0.21 (-8.97%)

(As of 02/9/2024 08:57 PM ET)

Compare

Today's Range: $2.11
▼
$2.45
50-Day Range: $0.67
▼
$2.78
52-Week Range: $0.66
▼
$10.50

Volume: 91,100 shs
Average Volume: 392,944 shs
Market Capitalization: $34.19 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $45.00

Get Alaunos Therapeutics alerts:

Alaunos Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Hold
2.33 Rating Score
Upside/Downside: 2,012.7% Upside
$45.00 Price Target
Short Interest: Bearish
11.98% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($2.10) to ($1.95) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.63 out of 5 stars

Medical Sector

768th out of 922 stocks

Pharmaceutical Preparations Industry

358th out of 425 stocks

3.2

Analyst's Opinion

Consensus Rating
Alaunos Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $45.00, Alaunos Therapeutics has a forecasted upside of 2,012.7% from its current price of $2.13.
Amount of Analyst Coverage
Alaunos Therapeutics has received no research coverage in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
11.98% of the float of Alaunos Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Alaunos Therapeutics has a short interest ratio ("days to cover") of 4.
Change versus previous month
Short interest in Alaunos Therapeutics has recently increased by 1.89%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Alaunos Therapeutics does not currently pay a dividend.
Dividend Growth
Alaunos Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for TCRT.

3.8

News and Social Media Coverage

News Sentiment
Alaunos Therapeutics has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.92 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Alaunos Therapeutics this week, compared to 0 articles on an average week.
Search Interest
Only 11 people have searched for TCRT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
7 people have added Alaunos Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 40% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Alaunos Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 6.18% of the stock of Alaunos Therapeutics is held by insiders.
Percentage Held by Institutions
Only 27.72% of the stock of Alaunos Therapeutics is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Alaunos Therapeutics are expected to grow in the coming year, from ($2.10) to ($1.95) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Alaunos Therapeutics is -0.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Alaunos Therapeutics is -0.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Alaunos Therapeutics has a P/B Ratio of 0.80. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Alaunos Therapeutics Stock (NASDAQ:TCRT)

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor engine. The company has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. was founded in 2003 and is headquartered in Houston, Texas.

TCRT Stock Price History

30 days | 90 days | 365 days | Advanced Chart

TCRT Stock News Headlines

February 4, 2024 | americanbankingnews.com

Alaunos Therapeutics (NASDAQ:TCRT) Stock Price Up 9%

February 3, 2024 | americanbankingnews.com

Alaunos Therapeutics (NASDAQ:TCRT) Shares Gap Down to $2.53

February 12, 2024 | The Freeport Society (Ad)

Biden Out, _______ In?

A new poll shows that two-thirds of Democrats want Biden to drop out of the 2024 race. The truth will shock you.

January 31, 2024 | msn.com

Alaunos Therapeutics Announces 1-for-15 Reverse Stock Split

January 31, 2024 | investing.com

Werewolf Therapeutics Inc (HOWL)

December 28, 2023 | benzinga.com

Alaunos Therapeutics Stock (NASDAQ:TCRT) Dividends: History, Yield and Dates

November 14, 2023 | benzinga.com

Recap: Alaunos Therapeutics Q3 Earnings

November 14, 2023 | investorplace.com

Why Is Alaunos Therapeutics (TCRT) Stock Up 14% Today?

February 12, 2024 | The Freeport Society (Ad)

Biden Out, _______ In?

A new poll shows that two-thirds of Democrats want Biden to drop out of the 2024 race. The truth will shock you.

November 14, 2023 | finance.yahoo.com

Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives

November 1, 2023 | morningstar.com

Alaunos Therapeutics Inc TCRT

August 15, 2023 | msn.com

Why Is Alaunos Therapeutics Sinking Today?

August 14, 2023 | finance.yahoo.com

Alaunos Therapeutics Announces Second Quarter 2023 Financial Results, Interim Clinical Data and Exploration of Strategic Alternatives

June 29, 2023 | finance.yahoo.com

Alaunos Therapeutics Announces Presentation at the 2nd Hawaii Global Summit on Thoracic Malignancies

June 9, 2023 | benzinga.com

Alaunos Therapeutics Stock (NASDAQ:TCRT), Insider Trading Activity

May 26, 2023 | msn.com

Alaunos slips 17% on Phase 1/2 data for cancer cell therapy

May 25, 2023 | finance.yahoo.com

Alaunos Therapeutics to Present Early Data from TCR-T Library Phase 1/2 Trial at 2023 American Society of Clinical Oncology Annual Meeting

May 17, 2023 | uk.news.yahoo.com

One Alaunos Therapeutics Insider Raised Stake By 117% In Previous Year

May 15, 2023 | seekingalpha.com

Alaunos Therapeutics upgraded to buy at Wainwright on multiple catalysts

May 13, 2023 | finance.yahoo.com

Alaunos Therapeutics, Inc. (NASDAQ:TCRT) Q1 2023 Earnings Call Transcript

May 11, 2023 | marketwatch.com

8-K: Alaunos Therapeutics, Inc.

May 10, 2023 | finanznachrichten.de

Alaunos Therapeutics, Inc.: Alaunos Therapeutics Reports First Quarter 2023 Financial Results

May 10, 2023 | msn.com

Alaunos Therapeutics GAAP EPS of -$0.04 in-line

May 10, 2023 | msn.com

Recap: Alaunos Therapeutics Q1 Earnings

May 10, 2023 | finance.yahoo.com

Alaunos Therapeutics Reports First Quarter 2023 Financial Results

May 3, 2023 | finance.yahoo.com

Alaunos Therapeutics to Report First Quarter 2023 Financial Results on May 10, 2023

April 26, 2023 | finance.yahoo.com

Alaunos Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

See More Headlines

Receive TCRT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alaunos Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/14/2023
Today: 2/11/2024
Next Earnings (Estimated): 3/05/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:TCRT
CUSIP: N/A
CIK: 1107421
Web: www.alaunos.com
Phone: (346) 355-4099
Fax: 617-241-2855
Employees: 34
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $45.00
High Stock Price Target: $45.00
Low Stock Price Target: $45.00
Potential Upside/Downside: +2,012.7%
Consensus Rating: Hold
Rating Score (0-4): 2.33
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.3988)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-37,730,000.00
Net Margins: N/A
Pretax Margin: -243,039.98%
Return on Equity: -140.74%
Return on Assets: -90.61%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.75
Quick Ratio: 2.75

Sales & Book Value

Annual Sales: $2.92 million
Price / Sales: 11.71
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.67 per share
Price / Book: 0.80

Miscellaneous

Outstanding Shares: 16,050,000
Free Float: 15,058,000
Market Cap: $34.19 million
Optionable: Optionable
Beta: -0.23

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

Mr. Dale Curtis Hogue Jr. (Age 54)
Interim CEO & Director
Mr. Michael Wong (Age 44)
Vice President of Finance & Principal Accounting Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

TCRT Stock Analysis - Frequently Asked Questions

Should I buy or sell Alaunos Therapeutics stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alaunos Therapeutics in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" TCRT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TCRT, but not buy additional shares or sell existing shares.
View TCRT analyst ratings or view top-rated stocks.
What is Alaunos Therapeutics' stock price target for 2024?: 3 brokerages have issued 1 year price targets for Alaunos Therapeutics' shares. Their TCRT share price targets range from $45.00 to $45.00. On average, they predict the company's stock price to reach $45.00 in the next twelve months. This suggests a possible upside of 2,012.7% from the stock's current price.
View analysts price targets for TCRT or view top-rated stocks among Wall Street analysts.
How have TCRT shares performed in 2024?: Alaunos Therapeutics' stock was trading at $1.0605 at the beginning of 2024. Since then, TCRT stock has increased by 100.8% and is now trading at $2.13.
View the best growth stocks for 2024 here.
When is Alaunos Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 5th 2024.
View our TCRT earnings forecast.

How were Alaunos Therapeutics' earnings last quarter?: Alaunos Therapeutics, Inc. (NASDAQ:TCRT) posted its quarterly earnings data on Tuesday, November, 14th. The company reported ($0.60) earnings per share for the quarter, missing analysts' consensus estimates of ($0.45) by $0.15.
When did Alaunos Therapeutics' stock split?: Shares of Alaunos Therapeutics reverse split on Thursday, February 1st 2024. The 1-15 reverse split was announced on Thursday, February 1st 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, February 1st 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.
Who are Alaunos Therapeutics' major shareholders?: Alaunos Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Commerce Bank (2.72%), Magnolia Capital Advisors LLC (0.17%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Kevin S Sr Boyle and Robert W Postma.
View institutional ownership trends.
How do I buy shares of Alaunos Therapeutics?: Shares of TCRT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TCRT) was last updated on 2/12/2024 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial